Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06015035 |
Recruitment Status :
Completed
First Posted : August 29, 2023
Last Update Posted : August 29, 2023
|
Sponsor:
Tang-Du Hospital
Information provided by (Responsible Party):
Xiaolong Yan, Dr., Tang-Du Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | April 1, 2022 |
Actual Study Completion Date : | April 1, 2022 |